APDA Is Proud To Join Parkinson's Action Network's Unified Partners Program


PAN's Unified Partners Program allows Parkinson's-related organizations to formally support PAN's work and strengthen the unified voice for better treatments and a cure for Parkinson's disease.

"We are thrilled to have APDA formally join PAN in our mission," said Ted Thompson, J.D., chief executive officer of PAN. "PAN has always served as the unified voice for the Parkinson's community in Washington, DC. This new program will allow PAN and the Unified Partners to drive more people to take action on federal policy issues that affect the one million Americans with Parkinson's disease."

As part of the Unified Partners Program, PAN offers organizations opportunities to get more deeply engaged on policy discussions that affect people with Parkinson's, their families, and their caregivers. Unified Partners and their supporters will have a more streamlined way to provide PAN with regular feedback that will inform policy objectives and strategies. PAN will provide the Unified Partners with public policy and communications resources to help facilitate more education and engagement with government officials.

"APDA is truly excited as we join forces with PAN to affect policy changes that will directly impact and improve the quality of life for those coping with PD," said Leslie A. Chambers, APDA President & CEO. "We are proud of our vast nationwide grassroots network and confident that our collective resources now as a PAN Unified Partner will play an important role in the legislative process while continuing to live out our mission to Ease the Burden - Find the Cure for millions of people impacted each day."

Learn more about the Unified Partners Program at


CONTACT: Stephanie Paul | 718-981-8062 | |

About the American Parkinson Disease Association

APDA was founded in 1961 with the dual purpose to Ease the Burden - Find the Cure for Parkinson's disease. In that time, APDA has raised and invested more than $86 million to fund research, patient services and education, and elevate public awareness. As the country's largest Parkinson's grassroots organization, APDA is here to serve the more than one million Americans with Parkinson's disease and their families through a nationwide network of Chapters, Information and Referral (I&R) Centers, and support groups. APDA also funds Centers for Advanced Research and awards grants to fund the most promising research toward discovering the cause(s) and finding the cure for Parkinson's disease.

About the Parkinson's Action Network

PAN is the unified voice of the Parkinson's community advocating for better treatments and a cure. In partnership with other Parkinson's organizations and our powerful grassroots network, PAN educates the public and government leaders on better policies for research and an improved quality of life for people living with Parkinson's. PAN was founded in 1991 and is a 501(c)(3) nonprofit organization. To learn more, visit


FDA Approves Two New Revolutionary Parkinson’s Medications

The American Parkinson Disease Association (APDA) is 
Dr. David G. Standaert working in the lab
excited to share that the U.S. Food and Drug Administration (FDA) has approved two new medications - RYTARY™ and DUOPA™ - as treatment for people with Parkinson’s disease. Both of these therapies offer a better way to deliver carbidopa and levodopa medication - and therefore help control symptoms. 
This is very exciting and hopeful news for the more than one million people living with Parkinson’s disease. Dr. David G. Standaert, Chairman of APDA’s Scientific Advisory Board says, “These are two very exciting new treatments which offer new opportunities to patients at different stages of their disease and help to better control their symptoms.” 
Key highlights about RYTARY™ 
RYTARY™ is an extended release formulation of carbidopa and levodopa and is manufactured by Impax Pharmaceuticals. RYTARY™ is designed to address one of the most significant unmet needs for people living with Parkinson’s disease, which is to reduce the amount of time during the day when their symptoms are not adequately controlled. 
People who take carbidopa and levodopa may find that over time that the drug becomes less effective and may experience a worsening of symptoms as the drug ceases to work successfully. As RYTARY™ is developed to FDA Approves Two New Revolutionary Parkinson’s Medications For more information, visit our website at, or call (800) 223-2732. To make a donation online, visit APDA-1505-NEWS-NL release more slowly over time it will maintain the levodopa levels and will provide greater treatment stability. This treatment will help those in the middle stages of Parkinson’s disease who have problems with the effects of their medication wearing off. 
Key highlights about DUOPA™ 
Developed by AbbVie, DUOPA™ is a new approach to the delivery of carbidopa and levodopa for the treatment of the motor symptoms of Parkinson’s disease. It is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine. 
DUOPA™ is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson’s disease. In a clinical trial, patients treated with DUOPA™ experienced significantly greater improvement in symptom control than patients treated with oral carbidopa and levodopa immediate release tablets. 
This treatment will help those in the advanced stages of Parkinson’s disease who cannot manage symptoms with regular tablets and other oral medications. 
APDA’s commitment to supporting clinical trials and improving outcomes is critical to our mission. We are honored that researchers funded by APDA participated in conducting the clinical trials that were critical in the FDA’s decision to approve these important new treatment options. This work is only possible because of our generous donors who have continued to partner with APDA to make a profound difference.

For more information, visit our website at, or call (800) 223-2732. To make a donation online, visit 


Financial Reimbursements for Parkinson's Medications
The Patient Access Network Foundation has announced that a co-pay program for Parkinson's patients will be opening on February 9. Co-pay programs provide direct financial assistance to qualified patients, assisting them with prescription drug co-payments their insurance requires relative to their diagnosis.

To determine eligibility you can contact the Patient Access Network Foundation by phone at (866-316-7263) or through the PAN Web site ( By answering a few questions you will learn immediately if you are eligible.